Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

PURPOSE: Despite therapeutic advances, outcomes for patients with platinum-resistant/refractory ovarian cancer remain poor. Selective glucocorticoid receptor modulation with relacorilant may restore chemosensitivity and enhance chemotherapy efficacy. METHODS: This three-arm, randomized, controlled,...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, Nicoletta, Van Gorp, Toon, Matulonis, Ursula A., Oaknin, Ana, Grisham, Rachel N., Fleming, Gini F., Olawaiye, Alexander B., Nguyen, Dorothy D., Greenstein, Andrew E., Custodio, Joseph M., Pashova, Hristina I., Tudor, Iulia C., Lorusso, Domenica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602497/
https://www.ncbi.nlm.nih.gov/pubmed/37364223
http://dx.doi.org/10.1200/JCO.22.02624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602497/
https://www.ncbi.nlm.nih.gov/pubmed/37364223
http://dx.doi.org/10.1200/JCO.22.02624

Ejemplares similares